BRIEF published on 08/28/2024 at 13:05, 1 year 8 months ago Rutherrin® Increases Efficacy of Chemotherapy for Lung Cancer Theralase® Technologies Inc. NSCLC Chemotherapy Rutherrin® Cisplatin
PRESS RELEASE published on 08/28/2024 at 13:00, 1 year 8 months ago Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer Theralase® announces significant enhancement of Cisplatin efficacy in chemotherapy resistant NSCLC using Rutherrin® drug formulation in preclinical studies. Combination therapy shows promising results for cancer treatment NSCLC Theralase Preclinical Studies Chemotherapy Rutherrin
BRIEF published on 08/21/2024 at 13:05, 1 year 8 months ago Theralase Demonstrates Activation of Rutherrin with Diabetes Drug Cancer Treatment Theralase Rutherrin Metformin ROS Production
BRIEF published on 08/21/2024 at 13:05, 1 year 8 months ago La théralase démontre l'activation de la rutherrine avec un médicament contre le diabète Traitement Du Cancer Theralase Rutherrin Metformine Production De ROS
PRESS RELEASE published on 08/21/2024 at 13:00, 1 year 8 months ago Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug Theralase Technologies Inc. announces innovative cancer treatment using Rutherrin activated by Metformin without light/radiation. Opens new patient care possibilities Innovation Theralase Technologies Inc. Cancer Treatment Rutherrin Metformin
BRIEF published on 08/12/2024 at 13:05, 1 year 9 months ago Theralase publie ses états financiers du deuxième trimestre 2024 Résultats Financiers Placements Privés Traitement Du Cancer Theralase Étude II
BRIEF published on 08/12/2024 at 13:05, 1 year 9 months ago Theralase Releases 2Q2024 Financial Statements Financial Results Private Placements Cancer Treatment Theralase Study II
PRESS RELEASE published on 08/12/2024 at 13:00, 1 year 9 months ago Theralase(R) Release’s 2Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the six-month period ended June 30, 2024. Conference call scheduled to review results. Study II progress and Break Through Designation update discussed Conference Call Financial Statements Theralase Technologies Inc. Break Through Designation Study II
BRIEF published on 07/08/2024 at 23:20, 1 year 10 months ago Theralase Closes $CAN 775,000 in First Tranche of Private Placement Private Placement Cancer Research Theralase Rutherrin Phase II Clinical Study
BRIEF published on 07/08/2024 at 23:20, 1 year 10 months ago Theralase clôture une première tranche de placement privé de 775 000 $CAN Placement Privé Recherche Contre Le Cancer Theralase Rutherrin Étude Clinique De Phase II
Published on 05/14/2026 at 15:10, 17 minutes ago Banyan Provides Summary of 2025 Diamond Drill Program for the Flagship AurMac Project, Yukon, Canada
Published on 05/14/2026 at 15:00, 27 minutes ago Karbon-X Explores Clean Cooking and Fish Smoking Climate Initiative Concept in Senegal
Published on 05/14/2026 at 15:00, 27 minutes ago ACCESS Newswire Celebrates PRSSA Bateman Competition Success and the Next Generation of Communications Leaders
Published on 05/14/2026 at 14:50, 37 minutes ago Germany's BGR Assesses NextSource Materials' Molo Graphite Mine as Part of Federal Critical Minerals Study
Published on 05/14/2026 at 14:30, 57 minutes ago Boron One Holdings Inc. Completes Its Jarandol Basin Exploration Program for 2026
Published on 05/14/2026 at 14:54, 33 minutes ago Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 05/14/2026 at 14:52, 35 minutes ago Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc
Published on 05/14/2026 at 09:03, 6 hours 24 minutes ago Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 21 hours 25 minutes ago ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES
Published on 05/13/2026 at 18:00, 21 hours 27 minutes ago ALTAREIT - Assemblée Générale Mixte du 4 juin 2026 - Modalités de mise à disposition des documents préparatoires
